ARS Pharmaceuticals’ (SPRY) Outperform Rating Reiterated at William Blair

ARS Pharmaceuticals (NASDAQ:SPRY)‘s stock had its “outperform” rating reiterated by William Blair in a note issued to investors on Friday,RTT News reports.

Several other brokerages also recently commented on SPRY. Oppenheimer assumed coverage on ARS Pharmaceuticals in a research note on Monday, February 10th. They issued an “outperform” rating and a $40.00 target price for the company. Raymond James boosted their target price on ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a “strong-buy” rating in a research note on Tuesday, January 14th. Finally, Leerink Partners boosted their target price on ARS Pharmaceuticals from $26.00 to $27.00 and gave the stock an “outperform” rating in a research note on Monday, January 13th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $28.80.

ARS Pharmaceuticals Price Performance

Shares of SPRY traded down $0.54 during trading hours on Friday, hitting $11.24. The stock had a trading volume of 1,380,737 shares, compared to its average volume of 1,297,939. The firm has a 50 day simple moving average of $12.02 and a 200-day simple moving average of $13.22. The firm has a market capitalization of $1.09 billion, a P/E ratio of -22.04 and a beta of 0.99. ARS Pharmaceuticals has a 1-year low of $7.50 and a 1-year high of $18.51.

Insider Buying and Selling

In related news, insider Sarina Tanimoto sold 100,000 shares of ARS Pharmaceuticals stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $13.16, for a total value of $1,316,000.00. Following the sale, the insider now owns 1,148,499 shares of the company’s stock, valued at approximately $15,114,246.84. The trade was a 8.01 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Laura Shawver sold 50,000 shares of ARS Pharmaceuticals stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $12.31, for a total transaction of $615,500.00. Following the completion of the sale, the director now directly owns 210,346 shares in the company, valued at $2,589,359.26. This trade represents a 19.21 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 617,102 shares of company stock valued at $7,935,840. 40.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On ARS Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. KLP Kapitalforvaltning AS bought a new stake in ARS Pharmaceuticals during the 4th quarter valued at $73,000. BNP Paribas Financial Markets bought a new stake in ARS Pharmaceuticals during the 4th quarter valued at $75,000. Ball & Co Wealth Management Inc. bought a new stake in ARS Pharmaceuticals during the 4th quarter valued at $105,000. Compass Capital Corp MA ADV bought a new stake in ARS Pharmaceuticals during the 4th quarter valued at $106,000. Finally, Teacher Retirement System of Texas bought a new stake in ARS Pharmaceuticals during the 4th quarter valued at $122,000. Institutional investors own 68.16% of the company’s stock.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.